Brockmöller, Jürgen

Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines

Rossi, S., Antal, A., Bestmann, S., Bikson, M., Brewer, C., Brockmöller, J., Carpenter, L. L., Cincotta, M., Chen, R., Daskalakis, J. D., et al. (2021) · Clinical Neurophysiology

Transcranial Magnetic Stimulation StudiesElectroconvulsive Therapy Studies

Cited by 1,573

Functional significance of a C–>A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine

Sachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1999) · British Journal of Clinical Pharmacology

Pharmacogenetics and Drug MetabolismCoffee research and impacts

Cited by 751

The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response

Biernacka, J. M., Sangkuhl, K., Jenkins, G., Whaley, R. M., Barman, P., Batzler, A., Altman, R. B., Arolt, V, Brockmöller, J., Chen, C. H., et al. (2015) · Translational Psychiatry

Treatment of Major DepressionGenetic Associations and Epidemiology

Cited by 140

Genetic Variants in FKBP5 Affecting Response to Antidepressant Drug Treatment

Kirchheiner, J., Lorch, R., Lebedeva, E., Seeringer, A., Roots, I., Sasse, J., & Brockmöller, J. (2008) · Pharmacogenomics

Treatment of Major DepressionStress Responses and Cortisol

Cited by 104

Pharmacogenetics‐Based New Therapeutic Concepts

Roots, I., Gerloff, T., Meisel, C., Kirchheiner, J., Goldammer, M., Kaiser, R., Laschinski, G., Brockmöller, J., Cascorbi, I., Kleeberg, U., et al. (2004) · Drug Metabolism Reviews

Pharmacogenetics and Drug MetabolismNutrition, Genetics, and Disease

Cited by 33